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*An intensifying crisis of opioid overdose within a crisis of COVID‐19 has opened the door to discussion of extending emergency measures for treatment, and possibly going even further to expand access*.

Widespread reports in recent months of a resurgence in opioid overdoses and related problems as the nation combats COVID‐19 are intensifying the call for greater flexibility in ensuring access to treatment for opioid use disorder (OUD). This is leading in some quarters to support for making some recently implemented emergency responses permanent, though there remains a general consensus that not enough concrete outcome data is yet available to fully evaluate the measures\' impact so far.

In an issue brief updated earlier this month, the American Medical Association (AMA) indicates that at least 30 states have reported some increases in opioid‐related mortality due at least partly to effects of the COVID‐19 crisis. The document calls on governors and state legislatures to take full advantage of the flexibility federal agencies have granted to ensure continuity of care for OUD, while also removing prior authorization and other long‐standing administrative barriers to more widespread use of OUD medications.

"We want the states to do more," Patrice Harris, M.D., who this month completed her term as AMA president, told *ADAW*. "We also need commercial insurers to step up and support patients\' treatment. Also, not all states have adopted harm‐reduction strategies," such as policies to improve access to syringe services programs and to enhance the safety of their operations.

Harris said it will be important to examine data closely before recommending whether policies such as expanded access to take‐home dosing of methadone should remain in place after the opioid treatment infrastructure returns to pre‐COVID‐19 levels of operation. But several leaders said last week that the relatively few anecdotal reports of misuse of medication during the pandemic suggest that emergency measures to maintain access to care have largely worked well.

"As medical director of an \[opioid treatment program\] in Baltimore, I\'ve seen how our patients have said they are so incredibly grateful for the ability to receive lifesaving treatment while staying in their homes," Yngvild Olsen, M.D., M.P.H., medical director of the Institutes for Behavior Resources Inc./REACH Health Services, told *ADAW*.

"Our patients\' average age is 50, and around 75% come to treatment with other underlying conditions," making them susceptible to the most adverse effects of COVID‐19, added Olsen, who serves as vice president of the American Society of Addiction Medicine\'s (ASAM\'s) board of directors.
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Where organizations\' views tend to diverge involves the discussion of more aggressive policy proposals, such as moves to dismantle or significantly alter provisions of the Drug Addiction Treatment Act (DATA 2000) governing buprenorphine treatment for OUD.

The presidents of the American Association for the Treatment of Opioid Dependence (AATOD) and the National Alliance for Medication Assisted Recovery (NAMA Recovery), in an uncommon show of unity between provider‐ and consumer‐based interests, last month wrote to a group of U.S. senators urging that they reconsider their request that the Department of Health and Human Services increase the maximum patient capacity for DATA 2000 waivered physicians from 275 to 500. AATOD and NAMA Recovery argue in the letter that not enough is known about the degree to which patients in DATA 2000 practices are receiving comprehensive care for OUD, and without this information it is difficult to make informed recommendations for policy changes. "**"As medical director of an \[opioid treatment program\] in Baltimore, I\'ve seen how our patients have said they are so incredibly grateful for the ability to receive lifesaving treatment while staying in their homes."**Yngvild Olsen, M.D., M.P.H."

"We do understand that it is not the intent of your correspondence to suggest that counseling is not necessary, but we are concerned that this could be an unintended consequence," states the May 4 letter from AATOD President Mark Parrino and NAMA Recovery President Zachary Talbott.

Parrino told *ADAW* that in the enthusiasm for doing something dramatic to combat the opioid crisis, some policy leaders are not taking the opportunity to examine broader issues, such as how to address reimbursement challenges, lack of clinical support for physicians and other barriers that help explain why only half of currently waivered physicians are actually prescribing buprenorphine. Instead, some leaders in addiction medicine seem to want to dismantle physician training requirements, characterizing that as a necessary emergency response, Parrino said.

Parrino said a more reasonable approach can be found in the proposed Medication Access and Training Expansion Act (H.R. 4974), a bill introduced in the U.S. House last November by a bipartisan group of members led by Rep. Lori Trahan (D‐Mass.). The legislation would impose a one‐time requirement for all prescribers of controlled substances to receive baseline training in evidence‐based addiction prevention and treatment. This training would fulfill DATA 2000 requirements as long as the waiver to prescribe buprenorphine remained in place.

There does seem to be broad agreement that amid the COVID‐19 pandemic, the "crisis within a crisis" of opioid overdose is worsening in many communities. The AMA issue brief references media reports of crisis conditions in more than half the states, including: Reports of a tripling of overdose rescues using naloxone by law enforcement in Arkansas since mid‐March, with suicide attempts by overdose increasing from an average of one per month to six.A more than doubling of deaths linked to opioid overdose in Cook County, Illinois, in the first five months of 2020 compared with the same period a year ago, with a disproportionate impact on the African‐American population of Chicagoans that is also being most severely affected by COVID‐19.A report that deaths from presumed overdose in Erie County, New York, totaled 85 in the first four months of this year compared with 48 in the same period in 2019, with more residents in their 50s affected than in the past. Drug court activity in Buffalo\'s municipal opioid court has been suspended during the pandemic, with the drug court not considered an essential government operation.

Among the AMA\'s far‐reaching recommendations for states to intervene on behalf of individuals with OUD during the pandemic are for justice settings to waive requirements for drug testing and in‐person counseling in order to maintain continuity of support for drug‐involved offenders in a safe environment.
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While the interviewed leaders want to see more data in the coming months on the impact of emergency measures to ensure access to care, they say anecdotal reports have largely been positive.

Regarding take‐home methadone, "There have been some reports of patients taking multiple doses," requiring medical treatment, Parrino said, but it has not been a groundswell. He added that COVID‐19 infection rates in opioid treatment programs have remained lower than those seen in the general public.

Olsen said that in Baltimore, the newfound flexibility to initiate a patient to buprenorphine treatment without an in‐person consultation (replaced by an audiovisual or telephone‐only contact) "has really allowed for continued access to treatment here."

She added, "As some states loosen restrictions on distancing, there is concern that these relaxations \[of regulatory requirements\] may be pulled back.... If we retreat to pre‐COVID operations, we will lose the ability to effectively continue caring for patients as the pandemic continues and evolves."
